BridgeBio Director Sells $754K in BBIO Stock, Exercises Options as Company Advances Late-Stage Program
BridgeBio Pharma director Scott Randal W. sold 10,000 shares of common stock on February 17, 2026, generating roughly $754,556 from multiple transactions priced between $74.3421 and $75.9261. The same day he exercised options to acquire 10,000 shares at $16.75 each for $167,500. After these moves he directly owns 11,589 shares and has an indirect h…